176 related articles for article (PubMed ID: 38096156)
21. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
22. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
23. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
24. Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas.
Mosaab A; El-Ayadi M; Khorshed EN; Amer N; Refaat A; El-Beltagy M; Hassan Z; Soror SH; Zaghloul MS; El-Naggar S
Sci Rep; 2020 May; 10(1):8368. PubMed ID: 32433577
[TBL] [Abstract][Full Text] [Related]
25. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
26. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
Damodharan S; Helgager J; Puccetti D
Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
[TBL] [Abstract][Full Text] [Related]
27. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
28. Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.
Zang D; Dong Z; Liu Y; Chen Q
BMC Neurol; 2024 Feb; 24(1):74. PubMed ID: 38383423
[TBL] [Abstract][Full Text] [Related]
29. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
30. H3K27M-mutant diffuse midline glioma presenting as synchronous lesions involving pineal and suprasellar region: A case report and literature review.
Lim JX; Leong A; Tan AP; Tan CL; Nga VDW
J Clin Neurosci; 2020 Nov; 81():144-148. PubMed ID: 33222904
[TBL] [Abstract][Full Text] [Related]
31. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
32. Diffuse midline glioma H3K27M mutation in adult: A case report.
Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
[TBL] [Abstract][Full Text] [Related]
33. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
Zhao H; Fang X; Xue B
Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
[TBL] [Abstract][Full Text] [Related]
34. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
35. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
[TBL] [Abstract][Full Text] [Related]
36. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
[TBL] [Abstract][Full Text] [Related]
37. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
[TBL] [Abstract][Full Text] [Related]
38. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
39. Histone-mutant glioma presenting as diffuse leptomeningeal disease.
Nadkarni T; Hamilton K; Niazi F; Ward M; Okakpu U; Castellani RJ; Prisneac I; Sener U
CNS Oncol; 2021 Sep; 10(3):CNS75. PubMed ID: 34469205
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
Messinger D; Harris MK; Cummings JR; Thomas C; Yang T; Sweha SR; Woo R; Siddaway R; Burkert M; Stallard S; Qin T; Mullan B; Siada R; Ravindran R; Niculcea M; Dowling AR; Bradin J; Ginn KF; Gener MAH; Dorris K; Vitanza NA; Schmidt SV; Spitzer J; Li J; Filbin MG; Cao X; Castro MG; Lowenstein PR; Mody R; Chinnaiyan A; Desprez PY; McAllister S; Dun MD; Hawkins C; Waszak SM; Venneti S; Koschmann C; Yadav VN
Neuro Oncol; 2023 Jan; 25(1):54-67. PubMed ID: 35605606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]